logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

Spain attracts more than 250 clinical trials in oncohematology in the last four years

Source: Farmaindustria.es

Various facts and arguments support the condition of Spain as an attractive country for the development of biopharmaceutical research projects: the quality of its health system, the prestige and recognition of its researchers, a highly advanced scientific and logistical infrastructure, the active commitment of patients , the experience and capacity of its pharmaceutical industry and pioneering legislation in Europe.

But it is the data that certifies that this positioning of the country among the best in the world is already a reality. In the last four years, Spanish hospitals hosted 259 clinical trials in the area of ??oncohematology, as discussed yesterday by Javier Urzay, deputy director of Farmaindustria, within the framework of the Haematological Cancer Seminar: from clinical research to medication access, organized by the Foundation for Health Research (FUINSA) and the Spanish Society of Hematology and Hemotherapy (SEHH) and held at the Ministry of Health, Social Services and Equality in Madrid.

As recorded in the Spanish Registry of Clinical Studies, between 2015 and 2018, 259 trials were carried out in Spain in the area of ??oncohematology, with some 1,700 participations in centers, and benefited more than 4,000 patients. This group includes studies on hematological cancer, blood cancer, leukemia and lymphoma, multiple myeloma, hematological neoplasia and lymphatic tissue. Urzay highlighted the fact that 60% of these projects are developed in the early stages (I and II), an indicator that is taken as a sample of the high capacity and preparation of the Spanish research tissue in this area.

Navarra and Castilla y León
He also noted as relevant the outstanding position of certain autonomous communities in the geographical distribution of this research activity. Together with leading communities such as Catalonia and Madrid and other communities with a large population such as Andalusia and Valencia, the cases of Castilla y León (where hematology accounts for 34% of all clinical research in the region) and Navarra (28%) stand out ), thanks to the existence of highly specialized centers in this field in Salamanca and Pamplona, ??respectively.

The industry is working together with clinical researchers, managers, administrations and patients to facilitate trials and provide greater treatment options for patients in a therapeutic area such as this where advances are beginning to revolutionize the approach to the disease.

The hematological neoplasms represent between 10% and 15% of the total of cancers, but they have a high socioeconomic impact since they are the ones with the highest incidence in children and young adults. Hematology is probably one of the fields in which personalized precision medicine is a more tangible reality for patients. Thanks to the knowledge of the genetic and molecular characteristics, the diagnosis is much more precise at present, which facilitates and accelerates the treatments.

The genetic complexity of these tumors and the importance of the personalization of treatments make it necessary to have referral units or centers and expert pathologists, specialized in this field.

In Distefar we echo this news which is a joy for our sector, since we are positioned among the first countries in the world of clinical trials in oncohematology.

Related entries

19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care


Leer más
14 September, 2023

Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros


Leer más
12 September, 2023

Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry


Leer más

Recent Posts

  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros
  • Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry
  • The rise of combination therapies in cancer opens up an opportunity for patients, but requires improved access procedures
  • The 22nd Meeting of the Spanish Pharmaceutical Industry will focus on the reform of European legislation and its impact on Spain

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.